PL2842945T3 - Pochodna sulfonamidowa i jej zastosowanie medyczne - Google Patents
Pochodna sulfonamidowa i jej zastosowanie medyczneInfo
- Publication number
- PL2842945T3 PL2842945T3 PL13781307T PL13781307T PL2842945T3 PL 2842945 T3 PL2842945 T3 PL 2842945T3 PL 13781307 T PL13781307 T PL 13781307T PL 13781307 T PL13781307 T PL 13781307T PL 2842945 T3 PL2842945 T3 PL 2842945T3
- Authority
- PL
- Poland
- Prior art keywords
- sulfonamide derivative
- medicinal use
- medicinal
- sulfonamide
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012098562 | 2012-04-24 | ||
JP2013054270 | 2013-03-15 | ||
EP13781307.7A EP2842945B1 (en) | 2012-04-24 | 2013-04-24 | Sulfonamide derivative and medicinal use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2842945T3 true PL2842945T3 (pl) | 2017-04-28 |
Family
ID=49483212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13781307T PL2842945T3 (pl) | 2012-04-24 | 2013-04-24 | Pochodna sulfonamidowa i jej zastosowanie medyczne |
Country Status (13)
Country | Link |
---|---|
US (1) | US9533985B2 (pl) |
EP (1) | EP2842945B1 (pl) |
JP (1) | JP6152093B2 (pl) |
KR (1) | KR101698796B1 (pl) |
CN (1) | CN104395297B (pl) |
BR (1) | BR112014026409B1 (pl) |
CA (1) | CA2871464C (pl) |
DK (1) | DK2842945T3 (pl) |
ES (1) | ES2609524T3 (pl) |
MX (1) | MX351225B (pl) |
PL (1) | PL2842945T3 (pl) |
RU (1) | RU2607081C2 (pl) |
WO (1) | WO2013161904A1 (pl) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106414413A (zh) * | 2013-10-29 | 2017-02-15 | Ea制药株式会社 | 磺酰胺衍生物及其药物用途 |
RU2016134749A (ru) * | 2014-01-28 | 2018-03-02 | ЕА Фарма Ко., Лтд. | Гетероциклическое сульфонамидное производное и лекарственное средство, содержащее такое производное |
WO2016128541A1 (en) * | 2015-02-13 | 2016-08-18 | Azienda Ospedaliera Universitaria Senese | Human helicase ddx3 inhibitors as therapeutic agents |
AU2017214589B2 (en) * | 2016-02-05 | 2020-09-03 | Ea Pharma Co., Ltd. | Sulfonamide derivative and pharmaceutical composition containing same |
WO2017135471A1 (ja) * | 2016-02-05 | 2017-08-10 | Eaファーマ株式会社 | α4β7インテグリン阻害剤 |
JP7035044B2 (ja) | 2016-11-11 | 2022-03-14 | ジーランド ファーマ エー/エス | α4β7インテグリンを標的とする環状ペプチド多量体 |
EP3621980A4 (en) | 2017-05-10 | 2021-06-30 | Zealand Pharma A/S | HOMODETIC CYCLIC PEPTIDES TARGETING INTEGRIN ALPHA4 BETA7 |
US11471459B2 (en) | 2018-03-26 | 2022-10-18 | Fondazione Per L'istituto Oncologico Di Ricerca (Ior) | Compounds with enhanced anti-tumor effects |
CN108752312A (zh) * | 2018-08-29 | 2018-11-06 | 常州沃腾化工科技有限公司 | 一种新的制备2-甲基-3-噻吩-5-甲氧羰基磺酰氯的方法 |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
CA3114240C (en) * | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
EP3873884A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
US20210403462A1 (en) | 2018-11-05 | 2021-12-30 | Syngenta Participations Ag | Pesticidally active azole-amide compounds |
JP2022525809A (ja) | 2019-03-22 | 2022-05-19 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺虫剤としてのn-[1-(5-ブロモ-2-ピリミジン-2-イル-1,2,4-トリアゾール-3-イル)エチル]-2-シクロプロピル-6-(トリフルオロメチル)ピリジン-4-カルボキサミド誘導体及び関連化合物 |
JP7491996B2 (ja) | 2019-08-14 | 2024-05-28 | ギリアード サイエンシーズ, インコーポレイテッド | α4β7インテグリンの阻害のための化合物 |
CN112830893A (zh) * | 2019-10-28 | 2021-05-25 | 成都倍特药业股份有限公司 | 一类RORγ抑制剂、其制备方法及其在医药上的应用 |
CN111574414A (zh) * | 2020-05-20 | 2020-08-25 | 上海毕得医药科技有限公司 | 一种4-溴-2-甲氧基苯磺酰氯的合成方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1325480C (zh) | 2000-08-18 | 2007-07-11 | 味之素株式会社 | 苯基丙氨酸衍生物 |
AU2002354224A1 (en) * | 2001-12-13 | 2003-07-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
WO2003089410A1 (fr) * | 2002-04-19 | 2003-10-30 | Kyowa Hakko Kogyo Co., Ltd. | Derive de phenylalanine |
US20070060480A1 (en) * | 2003-12-19 | 2007-03-15 | Matthias Witschel | Heteroaroyl-substituted phenylalanineamides |
RU2390520C2 (ru) | 2003-12-22 | 2010-05-27 | Адзиномото Ко., Инк. | Новые производные фенилаланина |
WO2005113003A2 (en) * | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting b cell depletion |
EP2103601B1 (en) * | 2006-11-22 | 2012-03-14 | Ajinomoto Co., Inc. | Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production |
WO2008064823A1 (en) | 2006-11-27 | 2008-06-05 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
ES2549768T3 (es) * | 2010-03-29 | 2015-11-02 | Ajinomoto Co., Inc. | Cristal de sal hidrocloruro de derivado de fenilalanina |
-
2013
- 2013-04-24 BR BR112014026409-0A patent/BR112014026409B1/pt active IP Right Grant
- 2013-04-24 US US14/397,078 patent/US9533985B2/en active Active
- 2013-04-24 JP JP2014512667A patent/JP6152093B2/ja active Active
- 2013-04-24 ES ES13781307.7T patent/ES2609524T3/es active Active
- 2013-04-24 EP EP13781307.7A patent/EP2842945B1/en active Active
- 2013-04-24 DK DK13781307.7T patent/DK2842945T3/en active
- 2013-04-24 CN CN201380033106.5A patent/CN104395297B/zh active Active
- 2013-04-24 WO PCT/JP2013/062121 patent/WO2013161904A1/ja active Application Filing
- 2013-04-24 PL PL13781307T patent/PL2842945T3/pl unknown
- 2013-04-24 RU RU2014146995A patent/RU2607081C2/ru active
- 2013-04-24 KR KR1020147032965A patent/KR101698796B1/ko active IP Right Grant
- 2013-04-24 CA CA2871464A patent/CA2871464C/en active Active
- 2013-04-24 MX MX2014012814A patent/MX351225B/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US20150051395A1 (en) | 2015-02-19 |
RU2014146995A (ru) | 2016-06-10 |
MX2014012814A (es) | 2015-05-08 |
CA2871464A1 (en) | 2013-10-31 |
BR112014026409B1 (pt) | 2022-09-06 |
EP2842945B1 (en) | 2016-10-26 |
EP2842945A1 (en) | 2015-03-04 |
EP2842945A4 (en) | 2015-09-16 |
MX351225B (es) | 2017-10-05 |
JP6152093B2 (ja) | 2017-06-21 |
BR112014026409A2 (pt) | 2018-09-18 |
KR101698796B1 (ko) | 2017-01-23 |
DK2842945T3 (en) | 2017-01-30 |
JPWO2013161904A1 (ja) | 2015-12-24 |
ES2609524T3 (es) | 2017-04-20 |
RU2607081C2 (ru) | 2017-01-10 |
WO2013161904A1 (ja) | 2013-10-31 |
US9533985B2 (en) | 2017-01-03 |
CA2871464C (en) | 2017-09-26 |
KR20150009558A (ko) | 2015-01-26 |
CN104395297B (zh) | 2016-05-04 |
CN104395297A (zh) | 2015-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274988A (en) | Carbamoylpyridone-polycyclic compounds and their pharmaceutical use | |
EP2842945A4 (en) | SULFONAMIDE DERIVATIVE AND MEDICAL USE THEREOF | |
IL234628A0 (en) | Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs | |
HK1203493A1 (en) | Substituted azabicycles and use thereof | |
EP2925202A4 (en) | SMOOTH AND VOLUMINOUS FABRIC | |
EP2828258A4 (en) | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE | |
EP2867209A4 (en) | COMPOUNDS AND THEIR THERAPEUTIC USES | |
ZA201501124B (en) | Trans-clomiphene formulations and uses thereof | |
EP2875014A4 (en) | ANTI-MUCUS MEDICAMENTS AND USES THEREOF | |
PT3064491T (pt) | Derivado de sulfonamida e sua utilização medicinal | |
EP2718283A4 (en) | INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
HK1203198A1 (en) | Substituted phenylimidazopyrazoles and use thereof | |
EP2817004A4 (en) | BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES | |
EP2837938A4 (en) | C1Q-ADIPONECTIN COMPLEX AND USE THEREOF |